Combined treatment with cotylenin A and phenethyl isothiocyanate induces strong antitumor activity mainly through the induction of ferroptotic cell death in human pancreatic cancer cells

Oncology Reports

Volumn 36, Issue 2, 2016, Pages 968-976

  Kasukabe, Takashi ^a   Honma, Yoshio ^a   Okabe Kado, Junko ^b   Higuchi, Yusuke ^c   Kato, Nobuo ^c   Kumakura, Shunichi ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Cotylenin A; Ferroptosis; Pancreatic cancer cells; Phenethyl isothiocyanate; Proliferation

Indexed keywords

3 METYLADENINE; ACETYLCYSTEINE; ADENINE DERIVATIVE; ANTINEOPLASTIC AGENT; CHLOROQUINE; COTYLENIN A; FERROSTATIN 1; GEMCITABINE; GLYCOSAMINOGLYCAN; LIPROXSTATIN; NECROSTATIN 1; PHENETHYL ISOTHIOCYANATE; REACTIVE OXYGEN METABOLITE; TROLOX C; UNCLASSIFIED DRUG; ANTIOXIDANT; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; CYCLOHEXYLAMINE DERIVATIVE; DITERPENE; FERROSTATIN-1; GLYCOSIDE; ISIR-042; ISOTHIOCYANIC ACID DERIVATIVE; PEPTIDE CHLOROMETHYL KETONE; PHENYLENEDIAMINE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLINE-VAL-ASP(OME)-CH2-OPH;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; PANCREATIC NEOPLASMS; TUMOR CELL LINE;

ACETYLCYSTEINE; AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLOHEXYLAMINES; DITERPENES; GLYCOSIDES; HUMANS; ISOTHIOCYANATES; PANCREATIC NEOPLASMS; PHENYLENEDIAMINES; QUINOLINES; REACTIVE OXYGEN SPECIES;

EID: 84976503884     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4867     Document Type: Article

References (38)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
3. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403-2413, 1997.
4. Kroep JR, Pinedo HM, van Groeningen CJ and Peters GJ: Experimental drugs and drug combinations in pancreatic cancer. Ann Oncol 10 (Suppl 4): S234-S238, 1999.
5. Jakstaite A, Maziukiene A, Silkuniene G, Kmieliute K, Gulbinas A and Dambrauskas Z: HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. World J Gastroenterol 21: 13004-13019, 2015.
6. Guilford JM and Pezzuto JM: Natural products as inhibitors of carcinogenesis. Expert Opin Investig Drugs 17: 1341-1352, 2008.
7. Higdon JV, Delage B, Williams DE and Dashwood RH: Cruciferous vegetables and human cancer risk: Epidemiologic evidence and mechanistic basis. Pharmacol Res 55: 224-236, 2007.
8. Tang L, Zirpoli GR, Guru K, Moysich KB, Zhang Y, Ambrosone CB and McCann SE: Intake of cruciferous vegetables modifies bladder cancer survival. Cancer Epidemiol Biomarkers Prev 19: 1806-1811, 2010.
9. Gupta P, Wright SE, Kim SH and Srivastava SK: Phenethyl isothiocyanate: A comprehensive review of anti-cancer mechanisms. Biochim Biophys Acta 1846: 405-424, 2014.
10. Satyan KS, Swamy N, Dizon DS, Singh R, Granai CO and Brard L: Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: Role of caspase and MAPK activation. Gynecol Oncol 103: 261-270, 2006.
11. Wu X, Zhou QH and Xu K: Are isothiocyanates potential anticancer drugs? Acta Pharmacol Sin 30: 501-512, 2009.
12. Hong YH, Uddin MH, Jo U, Kim B, Song J, Suh DH, Kim HS and Song YS: ROS accumulation by PEITC selectively kills ovarian cancer cells via UPR-mediated apoptosis. Front Oncol 5: 167, 2015.
13. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, et al: Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10: 241-252, 2006.
14. Xiao D, Powolny AA, Moura MB, Kelley EE, Bommareddy A, Kim SH, Hahm ER, Normolle D, Van Houten B and Singh SV: Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem 285: 26558-26569, 2010.
15. Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, Lewis TA, Maglathin RL, Tolliday N and Jacks T: Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci USA 108: 8773-8778, 2011.
16. Yang WS and Stockwell BR: Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 15: 234-245, 2008.
17. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al: Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149: 1060-1072, 2012.
18. Yang WS and Stockwell BR: Ferroptosis: Death by lipid peroxidation. Trends Cell Biol 26: 165-176, 2016.
19. Sassa T, Tojyo T and Munakata K: Isolation of a new plant growth substance with cytokinin-like activity. Nature 227: 379, 1970.
20. Asahi K, Honma Y, Hazeki K, Sassa T, Kubohara Y, Sakurai A and Takahashi N: Cotylenin A, a plant-growth regulator, induces the differentiation in murine and human myeloid leukemia cells. Biochem Biophys Res Commun 238: 758-763, 1997.
21. Yamamoto-Yamaguchi Y, Yamada K, Ishii Y, Asahi KI, Tomoyasu S and Honma Y: Induction of the monocytic differentiation of myeloid leukaemia cells by cotylenin A, a plant growth regulator. Br J Haematol 112: 697-705, 2001.
22. Yamada K, Honma Y, Asahi KI, Sassa T, Hino KI and Tomoyasu S: Differentiation of human acute myeloid leukaemia cells in primary culture in response to cotylenin A, a plant growth regulator. Br J Haematol 114: 814-821, 2001.
23. Honma Y: Cotylenin A-A plant growth regulator as a differentiation-inducing agent against myeloid leukemia. Leuk Lymphoma 43: 1169-1178, 2002.
24. Kasukabe T, Okabe-Kado J, Kato N, Honma Y and Kumakura S: Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells. Int J Oncol 46: 841-848, 2015.
25. Kawakami K, Hattori M, Inoue T, Maruyama Y, Ohkanda J, Kato N, Tongu M, Yamada T, Akimoto M, Takenaga K, et al: A novel fusicoccin derivative preferentially targets hypoxic tumor cells and inhibits tumor growth in xenografts. Anticancer Agents Med Chem 12: 791-800, 2012.
26. Kasukabe T, Okabe-Kado J, Kato N, Sassa T and Honma Y: Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res 7: R1097-R1110, 2005.
27. Kasukabe T, Okabe-Kado J, Haranosono Y, Kato N and Honma Y: Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells. Int J Oncol 42: 767-775, 2013.
28. Miyake T, Honma Y, Urano T, Kato N and Suzumiya J: Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells. Int J Oncol 47: 315-324, 2015.
29. Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch A, Eggenhofer E, et al: Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 16: 1180-1191, 2014.
30. Xargay-Torrent S, López-Guerra M, Montraveta A, Saborit-Villarroya I, Rosich L, Navarro A, Pérez-Galán P, Roué G, Campo E and Colomer D: Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma. Clin Cancer Res 19: 586-597, 2013.
31. Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB, Goossens V, Roelandt R, Van Hauwermeiren F, Libert C, et al: Necrostatin-1 analogues: Critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis 3: e437, 2012.
32. Carew JS, Nawrocki ST, Giles FJ and Cleveland JL: Targeting autophagy: A novel anticancer strategy with therapeutic implications for imatinib resistance. Biologics 2: 201-204, 2008.
33. Keum YS, Jeong WS and Kong AN: Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms. Mutat Res 555: 191-202, 2004.
34. Chen YR, Wang W, Kong AN and Tan TH: Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates. J Biol Chem 273: 1769-1775, 1998.
35. Yang YM, Conaway CC, Chiao JW, Wang CX, Amin S, Whysner J, Dai W, Reinhardt J and Chung FL: Inhibition of benzo(a)pyrene-induced lung tumorigenesis in A/J mice by dietary N-acetylcysteine conjugates of benzyl and phenethyl isothiocyanates during the postinitiation phase is associated with activation of mitogen-activated protein kinases and p53 activity and induction of apoptosis. Cancer Res 62: 2-7, 2002.
36. Jutooru I, Guthrie AS, Chadalapaka G, Pathi S, Kim K, Burghardt R, Jin UH and Safe S: Mechanism of action of phenethylisothiocyanate and other reactive oxygen species-inducing anticancer agents. Mol Cell Biol 34: 2382-2395, 2014.
37. Kasukabe T, Okabe-Kado J and Honma Y: Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2. Cancer Sci 99: 1693-1698, 2008.
38. Mujumdar N, Mackenzie TN, Dudeja V, Chugh R, Antonoff MB, Borja-Cacho D, Sangwan V, Dawra R, Vickers SM and Saluja AK: Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways. Gastroenterology 139: 598-608, 2010.